According to a publication from EurekAlert, results from a phase 1b clinical study of experimental glioblastoma “vaccine“ IGV-001 suggest that the treatment is well tolerated in humans. Additional data collected…
According to an article from Drugs.com, MediciNova Inc. has announced the first enrollment in its phase 1/2 clinical trial of MN-166, an experimental drug that hopes to target recurrent glioblastoma…
Early this month, Novocure announced that the first patient was enrolled in the RTOG Foundation's Phase 2 pilot trial for recurrent glioblastoma. This trial is aimed to test the safety and…
The week before last, innovative biopharmaceutical company DelMar, presented data at the Pediatric Neuro-Oncology Basic and Translational Research Conference from a clinical research with VAL-083 in chemo-resistant glioblastoma patients. Glioblastoma is…
© Copyright 2024 Patient Worthy
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
